What is 10x Genomics's gross profit margin?

What were the key takeaways from 10x Genomics's earnings call?

What does 10x Genomics do and what are its main business segments?

What is the revenue and EPS growth rate for 10x Genomics year over year?

What guidance did 10x Genomics's management provide for the next earnings period?

Did 10x Genomics beat or miss consensus estimates last quarter?

What factors drove the changes in 10x Genomics's revenue and profit?

What were the key takeaways from 10x Genomics’s earnings call?

- **Revenue Growth**: Q3 revenue of $149M exceeded guidance, with spatial consumables up 19% YoY and Flex-driven single-cell growth.
- **Product Innovation**: Xenium protein launch enables multi-omics analysis; Flex v2 reduces cost per sample for large-scale experiments.
- **Market Momentum**: Europe and China show resilience; Xenium adoption outpaces Visium.
- **Financial Strength**: $482M cash provides flexibility; Q4 guidance of $154-158M reflects steady growth.
- **Strategic Focus**: Virtual cell modeling and clinical collaborations drive long-term potential.

**【CEO Summary Section】**
- **Revenue Performance**: Q3 revenue of $149 million exceeded guidance, with spatial consumables growing 19% YoY and single-cell consumables up 10% YoY. Flex and On-Chip Multiplexing assays drove growth, particularly in translational studies.
- **Product Momentum**: Xenium protein consumables launched in Q3, enabling RNA and protein detection in a single run. Flex v2 assay reduces cost per sample, targeting large-scale experiments and AI-driven initiatives like virtual cell modeling.
- **Market Expansion**: Europe saw strong spatial consumables growth, while China showed resilience despite macro challenges. Xenium adoption is outpacing Visium due to its imaging-based workflow and multi-omics capabilities.
- **Strategic Investments**: $482 million in cash provides flexibility for innovation, including partnerships (e.g., Anthropic for AI-driven data analysis) and clinical collaborations (e.g., PERIBLOOD trial for blood diagnostics).

**【CFO Financial Commentary】**
- **Q3 Financials**: Total revenue $149 million (-2% YoY), with consumables ($127.9M) and services ($8.1M) up 1% and 29% YoY. Gross margin 67% (down 3ppt YoY due to product mix). Operating loss narrowed to $32.2M (-22% YoY).
- **Q4 Guidance**: Revenue $154-158M (+5% QoQ), driven by instruments and consumables. No material impact from U.S. government shutdown beyond intramural NIH (small fraction of revenue).
- **Balance Sheet**: Cash of $482M (+$35M QoQ) supports long-term growth and innovation.

**【Q&A Highlights】**
- **Spatial vs. Single-Cell**: Xenium adoption accelerating as researchers prefer imaging-based workflows. Flex v2 lowers cost per sample but volume growth offsets price declines.
- **China Dynamics**: Go-to-market improvements and strong demand, despite macro uncertainty.
- **Pharma Spending**: Cautious in early-stage R&D but interest in large-scale experiments for AI drug discovery and translational studies.
- **2026 Outlook**: First half likely similar to 2025H2, with no visibility on budget flushes. Long-term focus on virtual cell modeling and clinical applications.

10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript

- **Revenue Resilience**: Q2 revenue $173 million, with $146 million core business despite 5% YoY decline. China growth 41% YoY.
- **Strategic Wins**: $68 million Bruker settlement boosts margins; Scale acquisition enhances single-cell scalability.
- **Product Momentum**: Chromium reaction volumes up YoY, spatial consumables +24% YoY, Xenium adoption accelerating.
- **Macro Challenges**: Academic funding uncertainty persists, with delayed projects and cautious spending.
- **Cash Strength**: $447 million cash, enabling strategic flexibility amid uncertain environment.

**【CEO Summary Section】**
- **Q2 Revenue**: Total revenue of $173 million, including a $68 million Bruker settlement. Excluding settlement, revenue was $146 million, down 5% YoY due to macro challenges.
- **China Performance**: APAC revenue grew 41% YoY, driven by $4 million of accelerated orders ahead of potential tariffs.
- **Product Momentum**: 
  - Chromium reaction volumes grew YoY and QoQ, driven by GEM-X Flex and Universal On Chip Multiplex.
  - Spatial consumables revenue up 24% YoY, with Xenium adoption expanding across translational research.
- **Strategic Acquisitions**: Announced Scale Biosciences acquisition to enhance single-cell scalability and affordability.
- **Customer Sentiment**: Academic funding remains uncertain, with cautious spending and delayed project timelines.

**【CFO Financial Commentary】**
- **Financial Highlights**: 
  - GAAP net income: $34.5 million (vs. $37.9 million loss YoY).
  - Gross margin: 72% (68% YoY), driven by settlement.
  - Operating expenses: $135.7 million (excluding settlement).
- **Q3 Outlook**: Revenue $140-144 million, reflecting ongoing macro challenges and $4 million China pull-forward.
- **Balance Sheet**: $447 million cash, supporting strategic initiatives.

**【Q&A Key Highlights】**
- **Bruker Settlement**: $68 million upfront payment, with $17 million quarterly installments. Royalties not included in Q3 guidance.
- **Scale Acquisition**: Complementary to existing tech, targeting large-scale single-cell experiments. Minimal near-term revenue impact.
- **China Dynamics**: Strong execution and tariff-driven acceleration, with Q3 normalization expected.
- **Funding Environment**: NIH budget clarity and grant disbursement key to unlocking spending. Customers remain cautious amid policy uncertainty.
- **Instrument Strategy**: Discounted Chromium placements to drive adoption, balancing short-term cost with long-term reagent revenue.


10x Genomics, Inc. (TXG) Q2 2025 Earnings Call Transcript

- **Q1 Revenue Resilience**: $138M core revenue (-2% YoY) driven by 5% consumables growth, despite 42% instrument decline.
- **Cost-Cutting Action**: 8% workforce reduction and $50M+ savings to preserve $427M cash balance.
- **Xenium Momentum**: 18% consumables growth; 80%+ Chromium sales now GEM-X Flex kits.
- **Biopharma Expansion**: Targeting 50%+ pharma revenue with AI-driven drug discovery partnerships.
- **Q2 Guidance**: $138-142M (1% sequential growth), reflecting macro uncertainty and limited visibility.


**【CEO Summary Section】**
- Q1 2025 revenue was $155 million, with $138 million excluding settlement-related revenue, down 2% YoY due to instrument revenue decline offset by strong consumables growth.
- 40-50% of revenue exposed to U.S. academic/government funding, with NIH caps and budget cuts causing delays and cancellations.
- Implemented 8% workforce reduction and $50M+ cost savings to protect balance sheet; Q2 revenue guidance: $138-142 million (1% sequential growth).
- Positive trends: double-digit Chromium reaction growth, Xenium consumables up 18%, APAC revenue +22%.
- New product launches (e.g., GEM-X Flex, Visium HD 3' Prime) driving adoption; biopharma pipeline expanding with AI-driven drug discovery partnerships.

**【CFO Financial Commentary】**
- Q1 GAAP net loss: $34.4 million; Non-GAAP EPS: $1.08 (vs. $0.95 prior guidance).
- Gross margin: 68% (66% YoY), driven by license/royalty revenue and lower manufacturing costs.
- Operating expenses: $144.8 million (-6% YoY), with R&D down 6% and SG&A up 5%.
- Cash position: $427 million; no dividend policy change; focused on liquidity preservation.
- 2025 cost-saving measures: $50M+ reduction, including $5.5-6.5M severance costs.

**【Q&A Key Highlights】**
- **Market Uncertainty**: Customers hesitant to commit to capital purchases amid NIH funding cuts; Q2 order patterns similar to Q1 with 1% sequential growth.
- **Instrument Decline**: Spatial instrument revenue down 49% YoY due to fewer sales; focus on consumables growth (Xenium +18%).
- **China Tariffs**: 10% of 2024 revenue from China; minimal supply chain impact; Singapore manufacturing mitigates risk.
- **Biopharma Expansion**: 50%+ long-term goal for pharma revenue; AI partnerships (e.g., Chan Zuckerberg Initiative) driving large-scale data generation.
- **Competitive Position**: Xenium adoption outpacing competitors; 80%+ of Chromium sales now GEM-X Flex kits.
- **2025 Outlook**: Withdrew full-year guidance; Q2 visibility limited by macro uncertainty; potential for sequential flattish growth or improvement.


10x Genomics, Inc. (TXG) Q1 2025 Earnings Call Transcript

- **2024 Performance**: Revenue $611M (-1% YoY) amid macro challenges, but spatial revenue +33% YoY. 
- **2025 Strategy**: 
  - Chromium pricing down to $0.01/cell, targeting volume growth. 
  - Spatial revenue to grow double digits. 
  - Biopharma share to expand from 15-20% to 50% via clinical-stage applications. 
- **Financial Outlook**: 
  - 2025 revenue $610-630M (0-3% growth). 
  - Gross margin ~67-68%. 
  - NIH funding uncertainty could impact $10-15M revenue. 
- **Key Risks**: 
  - Chromium ASP decline (11% in 2024). 
  - NIH indirect cost cap uncertainty. 
  - Xenium instrument sales lagging in Q4 (-51% YoY).

**【CEO Summary Section】**
- Total revenue for 2024 was $611 million, down 1% YoY, driven by macro challenges and product transitions. 
- Key 2024 achievements: 
  - Chromium platform: Introduced GEM-X architecture with $0.01/cell pricing, 1M-cell experiments on single chip. Chromium Xo instrument launched for low-cost entry. 
  - Spatial platforms: Visium HD achieved 3x resolution improvement; Xenium Prime 5K launched with 5,000-gene flexibility. Spatial revenue grew 33% YoY. 
  - Sales reorganization: Specialized teams for pharma, academia, and capital equipment. 
- 2025 priorities: 
  - Complete product portfolio transition to new platforms. 
  - Democratize single-cell with lower prices (e.g., $600/sample on-chip multiplexing). 
  - Expand biopharma share from 15-20% to 50%+ via translational studies and large-scale projects (e.g., Chan Zuckerberg Initiative's 1B cell project). 
  - Maintain disciplined cost management to preserve $393M cash balance.

**【CFO Financial Commentary】**
- Q4 2024 Results: 
  - Total revenue: $165M (-10% YoY, +9% QoQ). 
  - Consumables: $133.5M (-5% YoY). Chromium: $97.7M (-17% YoY); Spatial: $35.8M (+61% YoY). 
  - Instruments: $24.4M (-37% YoY). Spatial instruments: $13.4M (-51% YoY). 
  - Gross margin: 67% (vs. 63% YoY), driven by lower Xenium instrument sales. 
  - Operating loss: $49.8M (vs. $55.2M YoY). 
- Full Year 2024: 
  - Total revenue: $611M (-1% YoY). 
  - Spatial consumables: $121.1M (+104% YoY). 
  - Gross margin: 68% (vs. 66% YoY). 
- 2025 Guidance: 
  - Revenue: $610-630M (0-3% YoY growth). 
  - Chromium consumables: Modest decline as lower-priced products gain share. 
  - Spatial revenue: Double-digit growth. 
  - Assumes 20-25% NIH funding exposure with mid-single-digit decrease in NIH projects.

**【Q&A Key Takeaways】**
- Pricing Strategy: 
  - Chromium price per reaction down 11% in 2024. Expect continued ASP decline in 2025 as GEM-X products dominate. 
  - Confident in demand elasticity; sequential reaction growth in Q4 suggests volume gains offsetting price cuts. 
- NIH Uncertainty: 
  - 2025 guidance excludes potential 8% NIH budget cut (could impact $10-15M revenue). 
  - Customers using direct funds for instruments, limiting immediate impact. 
- Biopharma Growth: 
  - Q4 2024 saw sequential improvement in pharma sales post-commercial reorg. 
  - FFP (formalin-fixed paraffin-embedded) compatibility across platforms enables clinical-stage applications. 
  - Targeting 50%+ revenue from pharma via translational studies and large-scale projects. 
- China Risks: 
  - <10% revenue exposure. Sequencing instrument compatibility reduces Illumina-related risks. 
  - No direct competitors for 10x technologies in China. 
- Gross Margin: 
  - 2025 margin expected to remain stable (~67-68%). Large projects may pressure margins but not baked into guidance. 
- Litigation: 
  - Vision settlement validates IP; no ongoing royalties. Positive precedent for Bruker case.


TXG

TXG fundamentals

Earnings Call

You can ask Aime